引用本文:李 伟,李东慧(综述),白进良(审校).非肌层浸润性膀胱癌灌注治疗现状及进展[J].中国临床新医学,2016,9(4):354-358.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 1765次   下载 1349 本文二维码信息
码上扫一扫!
分享到: 微信 更多
非肌层浸润性膀胱癌灌注治疗现状及进展
李 伟,李东慧(综述),白进良(审校)
730000 甘肃,兰州大学第一临床医学院(李 伟);730000 甘肃,兰州大学第一医院泌尿外科(李 伟,白进良);730000 兰州,甘肃省人民医院内分泌科(李东慧)
摘要:
[摘要] 膀胱癌是泌尿系统最常见的恶性肿瘤之一,临床上分非肌层和肌层浸润性膀胱癌(T2以上)两型,前者即以往所指的表浅性膀胱癌,约占70%,包括原位癌(Tis)、Ta及T1。膀胱癌呈表面和浸润性两方向生长,复发与转移是它的特征。治疗膀胱癌的方法虽多,疗效却不理想。该文就膀胱癌灌注治疗现状及进展作一综述。
关键词:  膀胱肿瘤  非肌层浸润性膀胱癌  浅表性膀胱癌  治疗  进展
DOI:10.3969/j.issn.1674-3806.2016.04.28
分类号:R 737.14
基金项目:
Current status and progress of bladder perfusion in the treatment of non-muscle-invasive bladder cancer
LI Wei, LI Dong-hui, BAI Jin-liang
Current status and progress of bladder perfusion in the treatment of non-muscle-invasive bladder cancer
Abstract:
[Abstract] Bladder cancer is one of the most common malignant tumors in the urinary system, which is divided into two types in clinic: bladder carcinoma with non muscular layer and muscular layer(T2 and above). The former which referred to superficial bladder cancer in the past accounts for 70%, including in situ carcinoma(Tis), Ta and T1. Bladder cancer grows surfacely and invasively, with the characteristics of recurrence and metastasis. There are some methods of the treatment of bladder cancer, but their clinical effects are not satisfying. In this article, we review the progress of bladder perfusion in the treatment of non-muscle-invasive bladder cancer.
Key words:  Bladder cancer  Non-muscle-invasive bladder cancer  Superficial bladder cancer  Treatment  Progress